Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in Millions of yen).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
The Childcare Support business reported higher earnings due to upward revisions to government-set service prices. The Nursing Care business also reported higher earnings due to an increase in the number of residents at hospice-care homes and the strengthening of its admissions sales structure. In the Pharmaceutical business, prescription volume increased, but higher revenue was accompanied by lower earnings due to drug price revisions and higher procurement costs for pharmaceuticals. The Other businesses reported higher revenue and earnings due to passing on higher costs and revising prices.
None (the notes on going concern state that there are no applicable matters)
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | 24,850 Millions of yen (YoY +4.3%) |
| Operating profit | 824 Millions of yen (YoY +28.6%) |
| Ordinary income | 827 Millions of yen (YoY +28.4%) |
| Profit attributable to owners of the parent | 200 Millions of yen (YoY -33.0%) |
| Net income per share | ¥71.83 |
| Operating Margin | 3.3% |
| Equity ratio | End of the current fiscal period 25.1% / End of previous period 28.6% |
| Total assets | 15,594 Millions of yen |
| Net assets | 3,914 Millions of yen |
| Cash flows from operating activities | 905 Millions of yen |
| Cash flows from investing activities | -363 Millions of yen |
| Cash flows from financing activities | 2,408 Millions of yen |
| Cash and cash equivalents at end of period | 4,483 Millions of yen |
| Full-year earnings forecast | Net Sales 25,200 Millions of yen (YoY +1.4%) / Operating profit 600 Millions of yen (YoY -27.2%) / Ordinary income 550 Millions of yen (YoY -33.6%) / Net income 360 Millions of yen (YoY +79.2%) |
| Annual Dividend Forecast | ¥30 → ¥30（0.0%） |
| Payout ratio | 41.8% |
| Segment revenue | Pharmaceuticals 9,947 Millions of yen (YoY +3.8%) / Childcare support business 10,294 Millions of yen (YoY +5.7%) / Nursing Care Business 3,538 Millions of yen (YoY -0.1%) / Other (Food business) 1,069 Millions of yen (YoY +11.0%) |
| Segment profit | Pharmaceuticals 502 Millions of yen (YoY -3.2%) / Childcare support business 1,257 Millions of yen (YoY +17.5%) / Nursing Care Business 55 Millions of yen (YoY +506.5%) / Other (Food business) 37 Millions of yen (YoY +134.7%) |
| Depreciation and amortization | 548 Millions of yen |
| Impairment loss | ¥454,302 thousand |
| Breakdown of extraordinary income (loss) | Extraordinary income Government subsidies for equipment and other assets ¥63,737 thousand, Compensation received ¥933 thousand / Extraordinary loss Loss on Disposal of Fixed Assets ¥1,066 thousand, Impairment Losses ¥454,302 thousand |
| Disclosure regarding the going concern assumption | None (the notes on going concern state that there are no applicable matters) |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate Yes / Restatement No |
| Changes in the scope of consolidation | Added: 0 companies; excluded: 0 companies (company names not disclosed) |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 2,802,300 shares |
| Treasury Shares at Period-End | 121 shares |
| Factors Behind Changes in Business Performance | The Childcare Support business reported higher earnings due to upward revisions to government-set service prices. The Nursing Care business also reported higher earnings due to an increase in the number of residents at hospice-care homes and the strengthening of its admissions sales structure. In the Pharmaceutical business, prescription volume increased, but higher revenue was accompanied by lower earnings due to drug price revisions and higher procurement costs for pharmaceuticals. The Other businesses reported higher revenue and earnings due to passing on higher costs and revising prices. |
Items this document does not state (4)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Childcare Support business benefited from upward revisions to government-set service prices, while profitability in the Nursing Care business improved as the number of residents at hospice-care homes stabilized. In the Pharmaceutical business, drug price revisions and higher procurement costs for pharmaceuticals reduced earnings, and the company recorded ¥454 million in impairment losses on fixed assets.